Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. Nov/Dec 2017;46(6):266-278.

Superior Capsular Reconstruction: Clinical Outcomes After Minimum 2-Year Follow-Up

Affiliations
  • PMID: 29309442

Superior Capsular Reconstruction: Clinical Outcomes After Minimum 2-Year Follow-Up

Alan M Hirahara et al. Am J Orthop (Belle Mead NJ). .

Abstract

Superior capsular reconstruction (SCR) is performed to reduce the pain and disability caused by irreparable supraspinatus rotator cuff tears (RCTs). In this article, we discuss 9 cases of irreparable rotator cuff tears managed with arthroscopic SCR with dermal allograft. At minimum 2-year follow-up (mean, 32.38 months), the patients were prospectively evaluated on the American Shoulder and Elbow Surgeons (ASES) shoulder index, a visual analog scale (VAS) for pain, acromial-humeral distance, and ultrasonography. Patients were compared before and after surgery and against historical controls who underwent repair of massive RCTs. From before surgery to 2 years after surgery, mean ASES score improved significantly (P < .00002), from 43.54 to 86.46, and mean VAS pain score decreased significantly (P < .00002), from 6.25 to 0.38. For the historical controls at final follow-up, mean ASES score was 70.71 (P = .11), and mean VAS pain score was 3.00 (P < .05). Mean acromial-humeral distance improved from 4.50 mm before surgery to 8.48 mm immediately after surgery (P < .0008) and 7.60 mm 2 years after surgery (P < .05). Ultrasonography revealed pulsatile vessels within the allograft tissue between 4 and 8 months after surgery. One patient underwent reverse total shoulder arthroplasty (RTSA) for anterior escape; another had the graft rupture after a motor vehicle accident. Our data showed SCR with dermal allograft effectively restored the superior restraints in the glenohumeral joint and yielded outstanding clinical outcomes even after 2 years, making it an excellent viable alternative to RTSA.

Conflict of interest statement

Authors’ Disclosure Statement: Dr. Hirahara reports that he receives consultant, royalty, and research support from Arthrex; is a consultant for LifeNet Health; and a medical advisor for Clarius Mobile Health. Dr. Panero reports that he is a consultant for Arthrex, and a speaker for Tenex Health and Lipogems. Mr. Andersen reports no actual or potential conflict of interest in relation to this article.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

LinkOut - more resources

Feedback